Your browser doesn't support javascript.
loading
Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
Lasrado, Ninaad; Rössler, Annika; Rowe, Marjorie; Collier, Ai-Ris Y; Barouch, Dan H.
Affiliation
  • Lasrado N; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Rössler A; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Rowe M; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Collier AY; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Barouch DH; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: dbarouch@bidmc.harvard.edu.
Vaccine ; 42(9): 2117-2121, 2024 Apr 02.
Article in En | MEDLINE | ID: mdl-38458874
ABSTRACT
A new highly mutated Omicron subvariant BA.2.87.1 has recently been identified with over 30 amino acid mutations in the Spike protein compared with BA.2, BA.5, XBB.1.5, and JN.1 variants. Mutiple mutations in BA.2.87.1 are located in the N-terminal domain (NTD) rather than in the receptor binding domain (RBD) of the Spike protein. We evaluated neutralizing antibody (NAb) responses to BA.2.87.1 because of its highly mutated sequence and its unique NTD region. Our data show that NAb responses to BA.2.87.1 were lower than to BA.2 but higher than to JN.1, suggesting that BA.2.87.1 is not a further antibody escape variant compared with other currently circulating variants. Moreover, XBB.1.5 mRNA boosting increased NAb titers to all variants tested including BA.2.87.1.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: En Journal: Vaccine Year: 2024 Document type: Article Affiliation country: Estados Unidos Country of publication: Países Bajos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: En Journal: Vaccine Year: 2024 Document type: Article Affiliation country: Estados Unidos Country of publication: Países Bajos